EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of T-LGL with Cyclosporine A-Long Term Follow-Up



Treatment of T-LGL with Cyclosporine A-Long Term Follow-Up



Blood 100(11): Abstract No 2635, November 16



T-LGL, a rare lymphoproliferative disorder caused by an expansion of activated cytotoxic T lymphocytes (CTLs), presents with the morphological appearance of circulating large granular lymphocytes and is associated with life threatening cytopenias and various autoimmune phenomena. The abnormal CTLs are believed to cause the cytopenia by suppressing hematopoiesis. Unlike the aggressive NK-cell variant of LGL leukemia, T-LGL responds to a variety of immunosuppressive agents: methotrexate, purine analogs and cyclosporine. We report the results of a trial of cyclosporine A (CyA) in the treatment of T-LGL patients with cytopenias (NIH-protocol 96-H-0142). Twenty-five consenting subjects (11 men, 14 women; median age 60, range (21-79)) with T-LGL and cytopenia had their diagnosis confirmed by morphology and flow cytometry. TCR gene-rearrangements could be detected in 19/25 by PCR or Southern blot. Ten subjects had coincident myelodysplasia (RA=6, RAEB=3, RARS=1). Several patients had immune dysregulation suggested either by history (15/25), abnormal immunoglobulin levels (12/25), elevated ANA (8/22) or elevated RF (8/22). Patients were treated with CyA 10mg/kg/day for at least three months, with subsequent taper. CyA was stopped in two patients, one on day 14 for serious neurological toxicity and the other on day 161 for erythroid hypoplasia. Follow up is between 36 and 72 months. Seven patients died and 18 survive. Five deaths were in nonresponders. About half the patients responded to CyA (13/25). Of these, six had complete normalization of blood counts. Most patients with a sustained response are dependent on low doses of CyA. Interestingly, one subject achieved a PR and two converted to a CR only after adding erythropoietin. Three out of the four responses seen in LGL-MDS had the RA subtype of MDS. Several possible factors to predict response were explored. Neither LGL count before or after therapy, marrow infiltration by LGL, marrow cellularity nor the presence of MDS had significant predictive value for response. In conclusion, continuous suppression of CTLs by low dose CyA maintains prolonged responses and is a reasonable treatment strategy for T-LGL.

(PDF 0-2 workdays service: $29.90)

Accession: 035980624

Download citation: RISBibTeXText



Related references

Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: a long-term follow-up. Cornea 27(2): 193-195, 2008

Cyclosporine A treatment for relapsed subcutaneous panniculitis-like T-cell lymphoma: a case with long-term follow-up. Korean Journal of Hematology 47(2): 146-149, 2012

Long-term cyclosporine A treatment does not progressively impair renal graft function: a 5-year follow-up study. Transplantation Proceedings 23(4): 2210-2210, 1991

Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up?. Transplantation Proceedings 33(1-2): 1461-1464, 2001

Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 80(2): 560-561, 1992

Cyclosporine A treatment in children with steroid-resistant and steroid-dependent nephrotic syndrome A comparison between long-term cyclosporine responders and cyclosporine late nonresponders. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 187A, September, 2001

Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Dermato-Venereologica 88(2): 117-120, 2008

Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft versus host disease in patients given hla identical marrow grafts for leukemia long term follow up of a controlled trial. Blood 73(6): 1729-1734, 1989

Long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine in chronic cyclosporine induced nephrotoxicity. European Heart Journal 23(Abstract Supplement): 512, August-September, 2002

The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. Bmc Nephrology 14: 42-42, 2013

Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplantation Proceedings 36(9): 2823-2825, 2004

Long-term follow-up of eczema patients treated with cyclosporine. Acta Dermato-Venereologica 78(1): 40-43, 1998

Elective conversion from cyclosporine to azathioprine: long-term follow-up. Transplantation Proceedings 19(1 Pt 3): 2017-2017, 1987

Long term histologic follow up of cyclosporine cs chronic nephrotoxicity. Pathology Research & Practice 185(1): 141, 1989